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A B S T R A C T
Osteosarcoma is the most common bone cancer among those with non-hematological origin and affects mainly
pediatric patients. In the last 50 years, refinements in surgical procedures, as well as the introduction of
aggressive neoadjuvant and adjuvant chemotherapeutic cocktails, have increased to nearly 70% the survival rate
of these patients. Despite the initial therapeutic progress the fight against osteosarcoma has not substantially
improved during the last three decades, and almost 30% of the patients do not respond or recur after the
standard treatment. For this group there is an urgent need to implement new therapeutic approaches. Oncolytic
adenoviruses are conditionally replicative viruses engineered to selectively replicate in and kill tumor cells,
while remaining quiescent in healthy cells. In the last years there have been multiple preclinical and clinical
studies using these viruses as therapeutic agents in the treatment of a broad range of cancers, including
osteosarcoma. In this review, we summarize some of the most relevant published literature about the use of
oncolytic adenoviruses to treat human osteosarcoma tumors in subcutaneous, orthotopic and metastatic mouse
models. In conclusion, up to date the preclinical studies with oncolytic adenoviruses have demonstrated that are
safe and efficacious against local and metastatic osteosarcoma. Knowledge arising from phase I/II clinical trials
with oncolytic adenoviruses in other tumors have shown the potential of viruses to awake the patient´s own
immune system generating a response against the tumor. Generating osteosarcoma immune-competent
adenoviruses friendly models will allow to better understand this potential. Future clinical trials with oncolytic
adenoviruses for osteosarcoma tumors are warranted.
1. Osteosarcoma: the disease
Compared to other tumors, bone cancers are relatively rare cancers
with an average incidence less than 1 per 100,000 person-year [1,2].
Bone cancers encompass different types of tumors, such as Ewing
sarcoma and chondrosarcoma, but the most frequent among them is
the osteogenic sarcoma, also known as osteosarcoma (OS), which
comprises a 20–40% of total new diagnosed bone cancers [2,3]. OS
tumors are characterized by the overproduction of an aberrant osteoid
matrix surrounding malignant spindle cells that leads to a high risk of
fracture within the affected bone [3,4]. Most of OS primary tumors are
located in the metaphysis of the long bones in both upper and lower
limbs, where there are developed about a 75–85% of the tumors [5,6].
However, the main issue of OS tumors is their high spread of malignant
cells along the organism and as a consequence most of the patients
present metastasis at the diagnosis, thus worsening the prognosis of
the disease.
The incidence of OS shows a bimodal age distribution with a major
peak observed during childhood and puberty, and a second minor peak
that appears in the elderly [2,5,7]. There are also gender related
differences in the epidemiology of OS, with an overall higher incidence
in males [1].
Although there is still a little knowledge about the etiology of OS,
the incidence characteristics described above, as well as, the predomi-
nant location of these tumors in limbs suggest a relationship between
bone growth and the development of the disease in young patients [8–
10]. On the other hand, OS in adults often appears as a secondary
malignancy [11] and the occurrence of these tumors has been linked to
some predisposing syndromes like Li-Fraumeni syndrome [12].
2. Osteosarcoma: treatment, survival and further needs
Before the arising of chemotherapy, the only treatment available for
OS was the amputation of the affected limb, even though the result was
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a poor survival rate below 20% of the patients [13]. Nowadays, the
standard protocol for high-grade OS includes the surgical resection of
the primary tumor and its metastases in combination with both
neoadjuvant and adjuvant therapies using different cocktails of high-
dose methotrexate with leucovorin rescue, adriamycin, cisplatin and
cyclophosphamide or ifosfamide [13]. As a result, this regimen has
increased the survival rate in the last 50 years up to a 60–70% of the
patients, as well as the evolution of imaging and surgery techniques has
improved the limb-salvage interventions over the 90% [13,14].
However, with the current strategies the success of OS treatment has
reached a plateau and the survival rate has not been increased in the
last 30 years. Moreover, besides the primary location within long
bones, OS is a highly metastatic tumor releasing invasive malignant
cells that migrates through the organism, thus leading to the develop-
ment of metastases in lungs [15–17] and, unfortunately, in those
patients with metastatic OS the survival rate drops to a poor 30% [18].
The lack of progress in the fight against OS is associated with the
presence of drug-resistant tumor cells [19]. In addition, some OS
tumors cannot be completely removed due to their location, especially
those affecting the axial skeleton.
On the other hand, the aggressiveness of the chemotherapeutic
treatment is associated with severe side effects including oocyte
destruction and infertility, hearing impairment, heart failure, hepato-
toxicity and nephrotoxicity [20–26].
For all these reasons, it is urgent to implement new therapeutic
approaches against osteosarcoma which allow improving the survival
rate as well as reducing the side effects. In the last years virotherapy
has emerged as a true potential strategy in cancer medicine. Currently
several viruses are being tested as anticancer agents, and among them
we will focus on oncolytic adenoviruses.
3. Adenoviruses: structure and viral cycle
Although there are dozens of different adenovirus described, all of
them share a common architecture. Adenoviruses are non-enveloped
viruses with an icosahedral capsid composed by up to 7 different
structural proteins. However, considering the scope of this review the
most relevant viral protein is the fiber due to its role in adenovirus
tropism. The fiber is a trimeric protein which is located on each of the
12 vertices of the virion and protrudes from the capsid as an elongated
antenna [27]. The fiber protein is composed of three domains (Fig. 1A):
1) a proximal tail domain that anchors the protein to the capsid; 2) a
distal globular knob domain that recognizes and binds to the cellular
receptor, and 3) a fibrous shaft domain which keeps the knob away
from the capsid, thus avoiding steric repulsion during the virus-cell
interaction.
On the other hand, the adenovirus genome is composed by a single
linear dsDNA molecule of about 36 kb long and encodes for more than
40 gene products clustered into different transcription units, which in
turn are named as early, intermediate or late depending on if they are
transcribed before, during or after the DNA replication, respectively
[28].
Regarding the viral cycle, first the adenovirus recognizes its specific
receptor on the cell surface triggering its internalization. Once inside
the cell the virus migrates through the microtubules and introduces the
viral genome inside the nucleus. There the E1A gene is expressed
immediately from the adenovirus genome. The E1A protein is able to
bind pRb [29–31], releasing the transcription factor E2F and thus the
arrest in the cell cycle. The release of E2F also triggers an orchestrated
activation of the viral genes that eventually will lead to the generation
of new virions, the lysis of the infected cell and the spread of the viral
progeny (Fig. 1B).
Additionally, the E1B-55k viral protein is also transcribed during
the initial stages of the infection and inhibits the tumor suppressor p53
to avoid its counterbalance effect in cell cycle progression as well as the
E1A-induced apoptosis mediated by p53 [32,33].
Among the different species and serotypes described, the human
adenovirus serotype 5 (Ad5) is, by far, the most studied adenovirus.
The Ad5 is a very common virus that has tropism for the upper
respiratory tract and usually causes just flu-like mild infections.
Nevertheless, besides its role as a natural human pathogen, in the last
three decades the interest of this virus has been boosted because of its
potential utility in different biomedical fields such as gene therapy,
vaccination and virotherapy [34–37]. Although there are some studies
using other adenovirus serotypes, the vast knowledge about the biology
of the Ad5, as well as its relatively harmless behavior are the main
reasons that places this serotype as the reference adenovirus in
biomedicine.
In this article we will review briefly the state-of-the art of Ad5
derivatives as therapeutic agents in the field of virotherapy and how are
they being tested to treat osteosarcoma.
4. Oncolytic adenoviruses as therapeutic tools: tumor
specificity
As described before, adenoviruses infect their target cells and
subsequently replicates inside the nucleus and lyses the cells to spread
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Fig. 1. A) Illustration showing the location of the fiber protein on the adenovirus capsid,
as well as the three structural domains of the fiber. B) Schematic adenovirus viral cycle.
The adenovirus recognizes its specific receptor (1) triggering its internalization inside the
cell (2). Then the virus migrates through the microtubules (3) and introduces the viral
genome inside the nucleus (4). The E1A gene is expressed immediately (5) the E1A
protein binds pRB releasing the transcription factor E2F and thus the cell cycle arrest (6),
which in turn will promote the expression of viral proteins and the genome replication,
obtaining the viral progeny (7).
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the progeny to infect new cells. This viral lytic cycle could be exploited
to destroy the cancer cells through several rounds of replication of the
adenovirus within the tumor mass (Fig. 2). However, this strategy may
confront some challenges to obtain a successful anti-cancer effect that
can be summarized as a replication of the virus restricted to cancer
cells and an enhanced tropism towards the tumor.
In regard to the cancer selectivity, different strategies have been
tested to generate conditionally replicative adenoviruses (CRAds)
whose replication is permissive only in cancer cells while remaining
innocuous to normal healthy cells (Fig. 3A). The prototypical CRAd was
the dl1520 virus, named with the trademark ONYX-015, which is
defective for E1B-55k protein [38]. Since E1B-55k is required for p53
shutdown, this virus was proposed as replicative only in p53 deficient
tumor cells, while in normal cells the normal p53 function would block
the viral replication [39]. Nevertheless, it was demonstrated that
dl1520 replication is independent from the p53 status of the tumor
[40,41]. Moreover, the dl1520 selectivity replication seems to be
related to other functions of E1B-55k like the late viral mRNA nuclear
export [42] and therefore, dl1520 oncolysis would be limited to those
tumors that complement the viral mRNA export.
Another strategy to achieve a cancer selective replication lies on the
mutation of the E1A transcription unit. In 2000 it was published by
Fueyo et al. [43] the generation of a CRAd named Delta24 carrying a
24-bp deletion in the second conserved region (CR2) of the E1A protein
(Fig. 3A). Considering that this region is involved in the binding of E1A
to pRb, the propagation of Delta24 is hindered in non-tumor cells
because of its inability to release the E2F required to promote the viral
replication. By contrast, the lack of a fully functional E1A protein does
not affects the virus replication in tumor cells since in most of the
tumors the pRb function is already impaired. Consequently, the
Delta24 adenovirus replicates in and kills cancer cells while remains
attenuated in normal cells.
A different approach to obtain CRAds is based on the replacement
of the E1A transcription unit promoter by tumor specific promoters
[44] (Fig. 3A), such as the promoters for the human telomerase
(hTERT) [45–47], the prostatic specific antigen (PSA) [48] or the α-
fetoprotein (AFP) [49], and so the viral gene expression and replication
can only be achieved in those tumors which activate these transgenic
promoters.
5. Oncolytic adenoviruses as therapeutic tools: widening
adenoviruses tropism
Besides the ability of the virus to replicate selectively in cancer cells,
it must be also considered its tropism towards the tumors. As described
previously, the virus recognizes its target cells trough the interaction of
the fiber protein with a specific viral receptor on the cell membrane.
The most common Ad5 receptor is the CAR protein (Coxsackie and
Adenovirus Receptor) [50,51], which participates in intercellular
unions within the tight junctions [52]. Nevertheless, the CAR protein
expression is down-regulated in many aggressive tumors [53–56], thus
hampering the adenovirus infection and so its oncolytic effect. To
overcome this barrier there have been engineered modifications of the
adenovirus fiber protein in order to retarget the virus to different
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Fig. 2. Schematic diagram representing the progression of the oncolytic adenovirus cycle
following the infection of a tumor cell versus a healthy cell. Although the virus is able to
infect normal healthy cells its replication is impaired, thus the cell remains undamaged.
On the contrary, the virus replicates in a tumor cell and generates new viral particles,
which in turn leads to the lysis of the cell and the spread of these particles to nearby cells.
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Fig. 3. Examples of strategies to obtain oncolytic adenoviruses with tumor selective
replication (A) or an enhanced tumor tropism (B and C). A) By mutating the E1A or E1B
genes the replication is restricted to pRB or p53 deficient cells, respectively. The
expression of E1A under tumor specific promoters, like human telomerase promoter
(hTERT), allows viral replication only in tumor cells. B) Generation of chimeric Ad5
viruses by fiber replacement from another serotype (AdX), thus obtaining an Ad5 with
the tropism of the AdX. C) Addition of the integrin binding motif CDCRGDCDC within
the knob domain of the fiber.
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receptors that could mediated the virus internalization in the cancer
cells (Figs. 3B and 3C).
One of the most preeminent examples of these modifications is the
insertion of an RGD peptide in the HI loop of the fiber knob domain
[57]. Since RGD is an αv-integrin binding motif, the addition of this
peptide allows the adenovirus attachment to different integrins, like
αvβ3 orαvβ5, and subsequently the virus infects the cell in a CAR-
independent manner [58]. The ability of this modified fiber to mediate
adenovirus infection in CAR-negative cells has been exploited in
multiple virotherapy studies for a broad range of tumors as for example
in glioma [59–61], osteosarcoma [62,63], ovarian cancer [64], prostate
cancer [65] or bladder cancer [66].
6. Clinical experience with oncolytic adenoviruses
Virotherapy has emerged as a novel innovative approach in the fight
against cancer. Nevertheless, despite the booming starting of virother-
apy its road to the clinic has been a long and windy one not exempt of
difficulties and drawback. In the early 2000s, multiple phase I and II
clinical trials were completed using the oncolytic adenovirus ONYX-
015 obtaining as a result a safety profile and moderate but promising
antitumor activity of the virus [67–70]. However due to a switch in
corporative strategies, the rights of ONYX-015 were sold to the Chinese
company Shanghai Sunway Biotech [71], thus leading to the impres-
sion that ONYX-015 was an ineffective therapeutic agent. Therefore,
the interest in oncolytic adenoviruses dropped during a few years. Later
on, Shanghai Sunway Biotech finished its phase III clinical trial using
the oncolytic adenovirus H101 (a modified ONYX-015), and its use has
been approved by the Chinese authorities for the treatment of
squamous cell cancer of head and neck (HNC) [72]. This adenovirus
(marketed under the brand name Oncorine) has demonstrated its
efficacy and safety in HNC in the phase III trial obtaining an overall
response rate nearly 80% in combination with cisplatin with only mild
flu-like symptoms as side effects [73]. However, it is important to
highlight that this treatment was approved by the Chinese Regulatory
Agency without any data regarding patient´s survival, nor the company
has reported information about overall survival.
Although adenovirus virotherapy has not been approved yet by any
Western country regulator, the “resurrection” of ONYX-015/H101 has
awaked the interest in oncolytic adenoviruses. As a result, at the
present we can find in the literature a plethora of clinical trials using
oncolytic adenoviruses for the treatment of different cancers, although
most of them are focused on the evaluation of the safety rather than
efficacy of the treatment.
As an example, two phase I clinical trials for the treatment of
patients affected by recurrent gynecologic cancers have been conducted
using the Delta24-RGD virus [74] or the Ad5/3-Δ24 virus [75], which
is a fiber chimeric Delta24 virus carrying the knob domain of the Ad3.
In both studies, the results shows a safety profile of the treatment since
only moderate side effect such as nausea or fatigue were attributable to
the viruses. Moreover, adenoviral replication was detected in ascites of
most of the patients, being detectable even nearly one month after the
treatment in those patients who received the highest dose. In regard to
clinical efficacy one month after the treatment with the oncolytic
adenoviruses nearly 60% of the patients show a stable disease under
RECIST criteria in both trials. Nevertheless, it must be considered that
RECIST criteria could be underestimating the potency of the treatment
since tumor pseudoprogression has been reported as a common
occurrence in virotherapy [76].
Recently the oncolytic virus Talimogene laherparepvec (T-VEC), an
attenuated herpes simplex type 1 (HSV-1) encoding the GM-CSF, has
been approved by the Western countries regulatory agencies for the
treatment of advanced melanoma [77]. Although T-VEC is not an
adenovirus, this is an important milestone in the field of virotherapy
since it is the first oncolytic virus being accepted by the Western
agencies, thus paving the way in the development of other oncolytic
viruses, such as adenoviruses.
7. Oncolytic adenovirus and osteosarcoma
In regard to osteosarcoma, there is still little data regarding the use
of oncolytic adenoviruses as therapeutic agents. Even though scarce,
several preclinical studies utilizing oncolytic adenoviruses have already
shown encouraging antisarcoma effect in human and in dogs
[62,63,78–81]. Despite the highly interesting model of canine OS, in
this study we focus in the use of oncolytic adenoviruses for human OS.
Since most of OS tumors are defective in the Rb pathway [82], the
CRAd Delta24 is an attractive platform to develop virotherapeutic
strategies against OS. One caveat to this strategy is that OS primary-
tumor cells as well as most OS cell lines express low levels of CAR
receptor. This is a major limiting factor to adenoviral infection [83,84].
For this reason, one of the first works on the use of oncolytic
adenovirus in OS, if not the first, employed a Delta24 virus containing
the RGD-4C insertion in the HI loop of the fiber knob (Delta24-RGD)
[62]. In this study, Witlox and colleagues demonstrated the presence of
αvβ3/5 integrins in OS primary cultures and cell lines and also their
higher susceptibility to an RGD modified virus infection in comparison
with an unmodified virus [62]. Also the oncolytic effect was assessed in
vitro obtaining as a result a massive reduction in OS primary and cell
line cultures viability after its incubation with low doses of Delta24-
RGD virus (MOI of 0.1 or 1), whereas at these doses the Delta24 virus
has no effect in cell viability except in the CAR-positive SaOS-2 cell
line. Then, the Delta24-RGD was administered intratumorally at
5×107 pfu in nude mice carrying subcutaneous primary human OS
xenografts, obtaining a delay in tumor growth of 11 days compared to
untreated animals. Moreover, they demonstrated that the virus was
able to replicate within the tumor. However, the virus was unable to
fully eradicate the xenograft, and the authors speculated this could be
due to an inefficient spread of the virus through the tumor matrix. It
must also be considered that this experiment was carried out in a
subcutaneous model, and the tumor environment may impact on the
tumor progression hampering the virus efficacy.
Later on, in 2008 the same group showed results obtained in a lung
metastatic nude mice model after the systemic administration of
Delta24-RGD [79]. The virus was administered intravenously at
1×109 pfu weekly during three consecutive weeks (weeks 1–3), and
also they performed a second experiment delaying the administration
of the virus 4 weeks (weeks 5–7). In both cases the systemic
administration of the adenovirus induced a reduction in the number
of pulmonary metastatic nodules. Again, they observed adenovirus
replication 3 weeks after the last administration of the virus, indicating
that tumor matrix did not block the spread of the virus within the
tumor. Surprisingly, the antitumor efficacy of Delta24-RGD was
slightly higher when the virus was administered with a 4-weeks delay.
The authors suggested a relationship between a higher vascularization
of the tumors and the ability of the virus to target the tumor cells
through an intravenous administration. Nevertheless, this affirmation
was just a hypothesis and was not contrasted.
As described above, tumor location could be an important factor
when it comes to its own progression and how the virus will exert its
anticancer effect. Therefore, it is important to evaluate the viral
antitumor efficacy in relevant orthotopic models. Recently, our group
published two studies where we evaluated the use of oncolytic
adenoviruses in sarcoma in local orthotopic, tibial, and lung metastatic
models [63,81]. In the first of these studies, 531MII human primary OS
cells were engrafted in the tibia of nude mice, and then Delta24-RGD
was administered intratumorally at a dose 3.8×107 pfu once a week
during three consecutive weeks, obtaining a significant reduction in
tumor burden [63]. We also evaluated a possible synergistic effect of
the Delta24-RGD in combination with cisplatin, which is used in the
current chemotherapeutic protocols for OS. We showed that unlike
other drugs used for the treatment of OS, such as doxorubicin, cisplatin
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does not interfere with viral replication. Moreover, the adenovirus
mediates an enhanced antitumoral effect of cisplatin since its IC50 in
vitro decreased to 1 logarithm due to the induction of autophagic cell
death. Regarding the in vivo studies, mice bearing lung metastatic OS
were treated with cisplatin and Delta24-RGD (intravenously at
2.5×108 pfu) weekly during three weeks. This combined regimen led
to a reduction of the tumor burden in the lungs, indicating that the
combination of Delta24-RGD and cisplatin could be an effective
treatment for metastatic lesions in osteosarcoma.
In a second study, our group evaluated the efficacy of the VCN-01
virus as a therapeutic agent in both orthotopic and metastatic models
of OS [81]. The VCN-01 is an oncolytic adenovirus whose E1A gene
also contains the Δ24 deletion in the pRb binding site, thus leading to a
selective replication in Rb deficient tumor cells [85]. However, this
virus contains two additional modifications to enhance its anticancer
effect. First, an RGD integrin binding motif has been placed in the fiber
shaft, replacing the putative heparan-sulfate proteoglycan binding
motif KKTK. This modification improves the tumoral tropism of the
virus as well as it abrogates the liver sequestration of the virus [86]. On
the other hand, this virus also encodes the PH20 hyaluronidase to
facilitate the spread of the virus within the extracellular matrix of the
tumor, allowing the virus to reach new target cells [87] (Fig. 4). To
evaluate the oncolytic activity of the VCN-01 in OS, the virus was
administered intratumorally at 107 or 108 pfu in nude mice bearing
orthotopic intratibial tumors. As a result, only a 30% of the tibias
treated with 107 pfu developed visible tumors at 90 days after the
engraftment, and none of the treated with 108 pfu did. Moreover,
visible tumors where observed in all untreated animals. Interestingly,
70% of the control animals presented also lung metastases, while the
development of metastases was completely abolished in the animals
treated with the higher dose of virus. These data underscored the
potent antiosteosarcoma effect of the VCN-01 in both the growth of the
primary tumors and the prevention of lung metastases. The efficacy of
VCN-01 was assessed also in nude mice with lung metastatic OS
tumors, and to this end the virus was administered intravenously at the
same doses as before. Once again, the tumor burden was reduced in the
animals treated with the VCN-01 compared to the control animals, as
they developed less metastatic nodules, which in turn where also
smaller. All together, the results obtained with the VCN-01 adenovirus
demonstrate its potential use as an effective therapeutic agent for the
treatment of osteosarcoma.
8. Future perspectives: immuno-virotherapy?
In the different studies explained above, oncolytic adenoviruses
showed promising results that validate these viruses as potential
candidates in the fight against osteosarcoma. Nevertheless, all the
studies published to date were performed in immunodeficient mice
models. One important lesson that we have learned from recent
oncolytic viruses-based clinical trials is that besides the lytic effect
that they induce through replication they also trigger systemic anti-
tumor immune responses. It is clear that a proper immune response
against the tumor is a key element that helps to achieve a successful
antitumor therapy, and the use of oncolytic adenoviruses may play an
important role in stimulating such immune reaction against tumor cells
by different mechanisms, such as an increase in the presentation of
tumor associated antigens (TAAs). Eventually, the cell death mediated
by the adenovirus would release tumor antigens which can be
presented to T-cell lymphocytes by the antigen presenting cells
(APC). The combination of the lytic activity of the virus and the
enhancement of the immune reaction could lead to a synergistic
antitumor effect. Therefore, in order to fully understand how preclini-
cal studies will translate to the clinic it would be very important to have
proper immunocompetent models and, consequently, lacking a com-
plete immune system may alter the results thus hindering the predic-
tion of these treatments in patients. Regarding immunocompetent
1
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Oncolytic adenovirus PH20 hyaluronidase Hyaluronic acid
Fig. 4. Schematic illustration showing an enhancement of the viral spread in the presence of a porous extracellular matrix (ECM). An infected tumor cell (1) will eventually produce new
infectious viral particles. The spread of a normal oncolytic adenovirus is hindered by a dense hyaluronic acid ECM (2). The VCN-01 adenovirus encodes the human hyaluronidase PH20,
which is secreted by the infected cell and, in turn, the hyaluronidase degrades the hyaluronic acid, facilitating the spread of the viral progeny through the ECM to new tumor cells (3).
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models to evaluate the efficacy and immune mechanisms triggered by
adenoviruses we come to a major hurdle which is the lack or low
replication of adenoviruses in murine cells [88–90]. This limitation has
led to a paucity of studies in immunocompetent models. Recently,
several works have addressed the effect of oncolytic adenoviruses in the
context of immunocompetent mice. Even though, one can argue these
are not the best models, at least, these experimental approaches have
provided clues regarding the possible effect of oncolytic viruses in
humans. Thus, it would be imperative to develop new animal models
which allow us to evaluate together the lytic activity of the virus and the
enhancement of the immune reaction against the tumor. In the recent
years, some groups have developed humanized mouse models which
contain a human immune system so human tumor cells can be
transferred to these mice, thus enabling to study the replication of
the oncolytic virus in an immunocompetent environment.
In summary, it is clear that in preclinical studies oncolytic
adenoviruses are effective against osteosarcoma. Further, clinical trials
will uncover if these non-pathogenic viruses fulfill the promise seen in
the lab. In addition, we are witnessing an exciting time for immu-
notherapy with the antibodies against the immune-checkpoints, CAR-T
cells and other immune strategies achieving success in the clinic for
some type of tumors. All these immune-therapies are amenable to
combine with oncolytic viruses opening the door to possible synergistic
combination. We hope that in the near future we can see the results in
the form of successful clinical trial based oncolytic adenoviruses for
those osteosarcomas that do not respond to the standard treatment.
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